Form D · Biotechnology

Nohla Therapeutics Inc.

Seattle, WA · CIK 0001662002

Offering snapshot reported May 16, 2018 · SEC filing

Reported sold
$45M
Offering amount: $58.4M
Investors reported
10
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 1, 2018
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 16, 2018Initial$44,999,999No comparison10SEC filing
Nov 16, 2017Amendment$32,356,803$20,356,804vs Dec 5, 201613SEC filing
Dec 5, 2016Initial$11,999,999No comparison3SEC filing
Dec 29, 2015Initial$2,024,998No comparison9SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-312535
These amounts exclude issuances of Company securities pursuant to Regulation S promulgated under the Securities Act of 1933, as amended.

Source: Form D, filed May 16, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Benjamin Scot Bergo Director, Executive, Promoter
Ian David Brown Director
Gary Christianson Executive
Brian Daniels Director
Colleen Delaney Executive
Kathleen Fanning Director, Executive
Steven Gillis Director
Lawrence Gozlan Director
Jim Johnson Executive
Darren Scotti Executive
Michael Sistenich Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1600 Fairview Ave E. Suite 100
Seattle, WA, 98102